Current Therapy of Chronic Myelogenous Leukemia

この論文にアクセスする

この論文をさがす

著者

抄録

Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder molecularly defined by the BCR-ABL gene and its products. The protein encoded by this chimeric gene is a constitutively activated tyrosine kinase that alters multiple signal transduction pathways inducing malignant transformation. Until recently, treatment options for patients with CML consisted of hydroxyurea, interferon-based therapies or allogeneic stem cell transplantation (alloSCT). Treatment decisions were generally based on the age of the patient and the phase of the disease. Recently, several new therapies have been developed that may change the natural history of CML and patient prognosis. In particular imatinib mesylate (STI571, Gleevec) an oral Bcr-Abl kinase inhibitor, has demonstrated activity in all phases of CML, and may replace interferon and alloSCT as the initial therapy for this disease. Other agents and therapies with potential value, either alone or in combination, include polyethyleneglycol (PEG) interferon, homoharringtonine, decitabine, oral cytarabine, and growth factor modulation. In this article, we discuss the biological and clinical characteristics of CML, as well as the different therapeutic alternatives for patients with this disorder.<br>(Internal Medicine 41: 254-264, 2002)

収録刊行物

  • Internal medicine

    Internal medicine 41(4), 254-264, 2002-04

    一般社団法人 日本内科学会

参考文献:  81件中 1-81件 を表示

被引用文献:  2件中 1-2件 を表示

各種コード

  • NII論文ID(NAID)
    10008354539
  • NII書誌ID(NCID)
    AA10827774
  • 本文言語コード
    ENG
  • 資料種別
    REV
  • ISSN
    09182918
  • NDL 記事登録ID
    6262678
  • NDL 雑誌分類
    ZS21(科学技術--医学--内科学)
  • NDL 請求記号
    Z53-M398
  • データ提供元
    CJP書誌  CJP引用  NDL  J-STAGE 
ページトップへ